遗传性痉挛性截瘫spastin、atlastin和paraplegin基因突变分析

目的探讨遗传性痉挛性截瘫(HSP)spastin、atlastin和parap legin基因的突变特点。方法应用聚合酶链反应-单链构象多态性(PCR-SSCP)结合DNA序列分析方法对24个常染色体显性遗传HSP家系和14例散发患者进行spastin基因和atlastin基因突变分析;对12个常染色体隐性遗传HSP家系和14例散发患者进行parap legin基因突变分析。结果在5个不同的常染色体显性遗传HSP家系中发现4个spastin基因新突变(1223 insCTCA、1258T→A,1293A→G和1668delCTA),在2例散发患者中发现2个spastin基因多态(IVS1-31C→G和IVS2-47A→G);在常染色体显性遗传HSP家系和散发患者中未发现atlastin基因突变或多态;在常染色体隐性遗传HSP家系和散发患者中未发现致病突变,仅在2例散发患者中发现2个parap legin基因多态(2063G→A及2066G→A)。结论我国遗传性痉挛性截瘫患者中spastin基因突变较常见,atlastin和parap legin基因的突变率可能较低。     

遗传性痉挛性截瘫中Atlastin基因和Nipa1基因同时突变一家系分析

目的通过分析遗传性痉挛性截瘫一家系中的基因突变，探讨此家系中两种基因突变同时发生的情况。方法应用ABD100遗传分析仪对该家系成员进行DNA测序，进行SPG3A／Atlastin和SPG6／Nipa1基因突变分析。结果遗传分析显示家系中先证者（Ⅱ2）和其女儿（Ⅲ1）既是SPG3A／Atlastin（SPG3A P344L）基因突变杂合体又是SPG6／Nipa1（SPG6 T100A）基因突变的杂合体。先证者的双亲均无SPG3A／Atlastin基因突变，但其父是一个携有SPG6／Nipa1（SPG6 T100A）基因突变的杂合体。结论该家系患者同时存在SPG3A/Atlastin和SPG6/Nipa1两种基因突变，其中SPG3AZ/Atlastin为新产生的非遗传突变。     

遗传性痉挛性截瘫一家系(SPG4)的临床与遗传学特点

目的 探讨遗传性痉挛性截瘫(HSP)4型患者的临床特点和基因突变. 方法观察HSP4型患者1个家系4例患者的临床特点,抽取家系5个成员的外周血,选择与已知HSP致病基因位点在物理距离上紧密连锁的微卫星分子STR进行标记.连锁分析并构建其单体型后进行突变筛选.结果 基因分型结果显示了D2S2351与D2S2255与致病基因不排除连锁.其他位点LOD值为负值排除连锁,因此初步定位于HSP致病基因(SPG)4,所对应的候选基因是spastin基因.突变筛查发现患者spastin基因第8外显子1168位置碱基A/G杂合突变.结论该HSP家系患者具有典型临床表现,为spastin基因第8外显子1168核苷酸的位置上A/G杂合突变所致.     

遗传性痉挛性截瘫2家系的临床特点与spastin基因突变分析

目的:探讨2个家系遗传3代以上常染色体显性遗传性痉挛性截瘫(AD-HSP)的临床特点及其与spastin基因突变的关系。方法:对2个AD-HSP家系进行详细的临床检查,总结所有患者临床特点,并应用PCR技术结合DNA序列分析方法,检测2家系先证者spastin基因的突变情况。结果:2家系中所有患者均具有HSP的典型表现,PCR-DNA序列分析2例先证者spastin基因的17个外显子均未发现有异常突变。结论:2家系HSP患者具有典型的AD-HSP临床表现,并非spastin基因外显子突变所致。     

遗传性痉挛性截瘫paraplegin基因的突变分析

目的探讨paraplegin基因在中国人遗传性痉挛性截瘫(HSP或SPG)中的突变特点,为该病的基因诊断奠定基础。方法应用聚合酶链反应单链构象多态性(PCRSSCP)结合DNA序列分析方法,对来自全国8个常染色体隐性遗传HSP家系的先证者和14例散发性HSP患者进行paraplegin基因突变分析。结果所有外显子均可扩出,发现15号外显子上2例先证者出现异常SSCP条带,经DNA序列分析发现2063及2066位点上存在碱基G被A替换,但家系内不存在共分离的现象,且正常对照者也存在G被A替换,考虑为多态,其中G2066A为首次发现。结论Paraplegin基因突变可能在中国人HSP患者中少见。2063G→A及2066G→A是paraplegin基因的两个多态性改变,其中2066G→A为首次发现。     

贵州部分少数民族遗传性痉挛性截瘫Spastin基因突变研究

目的筛查及分析遗传性痉挛性截瘫(HSP)Spastin基因突变,了解贵州地区少数民族(彝族、布衣族、苗族)Spastin基因突变特点。方法应用PCR产物直接DNA测序法,对9例HSP患者(包括3个家系中7例现证者和2例散发患者)Spastin基因1-17号外显子进行突变筛查;被发现存在突变的外显子,其次行家系内其他成员相对应外显子的筛查。结果在9例HSP患者中发现家系3两例患者(Ⅴ24、Ⅴ25)的Spastin基因第4号外显子同一位点上发生错义突变c.847C>T,其他参与抽血的亲属均无该位点突变,推测该位点的突变为一多态。另外的突变位点均位于外显子序列前后的内含子区域。结论此次贵州地区部分少数民族spastin基因突变率低,与国内文献报道的汉族人群不同。     

家族性低钾型周期性麻痹的基因突变与临床特征

目的筛查家族性低钾型周期性麻痹相关基因突变位点,总结该病基因型和临床表型的相关性.方法应用聚合酶链反应（PCR）和DNA测序技术,对14个家族性低钾型周期性麻痹家系中的14例先证者进行候选基因CACNA1S、SCN4A、KCNE3的筛查,阳性者再对其家系中其他患者和健康亲属进行测序分析.结果14个家系中有3个家系其先证者存在已知的低钾型周期性麻痹相关突变（1个家系发生CACNA1S基因R1239H突变,2个家系发生SCN4A基因的R672H突变）.进一步对3个突变家系中4例其他患者和34名健康亲属测序分析发现,R1239H突变为完全外显率,R672H突变为不全外显率.同时还发现2种突变在发病年龄和乙酰唑胺的疗效等方面存在差异.结论中国低钾型周期性麻痹患者存在CACNA1S基因R1239H和SCN4A基因的R672H突变,2种突变的临床表型存在差异.     

伴皮质下梗死及白质脑病常染色体显性遗传性脑动脉病的NOTCH3基因诊断

目的 分析伴皮质下梗死及白质脑病常染色体显性遗传性脑动脉病((CADASIL)的NOTCH3基因突变类型.方法 对临床诊断为CADASIL的4例先证者、来自3个家系10例患者及4例无类似临床表现成员、以及100名健康对照者进行NOTCH3基因PCR扩增及变性高压液相色谱分析(DHPLC)检测;对DHPLC阳性结果进行DNA双向测序,明确致病性突变或多态类型.结果 在CADASIL先证者及其家系患者中共发现134半胱氨酸→酪氨酸(Cys134Tyr)、141精氨酸→半胱氨酸(Arg141Cys)、90精氨酸→半胱氨酸(Arg90Cys)3种突变类型,存在于第3、第4外显子,为杂合错义突变.同时发现15种多态类型.其中家系1和家系2中分别发现1名成员与先证者存在相同位点的NOTCH3基因致病性突变,尚未出现与先证者相应的临床表现,被确定为临床前期患者.结论 NOTCH3单基因突变是CADASIL的分子遗传学基础,第3、4外显子可能是中国CADASIL家系的热点突变区.第4外显子Cys134Tyr突变类型为国内首次报告.     

家族性低钾型周期性麻痹基因型和表型分析

研究背景分析一中国汉族家族性低钾型周期性麻痹家系的致病基因和相关临床资料。方法采用DNA序列技术对先证者(Ⅲ3)进行CACNA1S、SCN4A、KCNE3全基因组筛查,针对检测到的变异进一步检测家系中其他患者和无症状家系成员是否存在相同基因突变,经对临床资料分析以确定相关基因突变是否为致病性突变基因。结果先证者(Ⅲ3)及家系中其他患者(Ⅱ1、Ⅲ4、Ⅳ3)均检测到CACNA1S基因IVS25-194C/T突变,而无症状家系成员(Ⅲ1)未检测到该突变;该家系成员(除Ⅰ1)均检测到SCN4A基因IVS18-130G/A突变,该位点位于内含子区域且有症状和无症状家系成员同时出现;先证者(Ⅲ3)和无症状家系成员(Ⅲ1)同时检测到SCN4A基因外显子12区域c.1984GA突变,系错义突变(V662I),但家系中其他患者(Ⅱ1、Ⅲ4、Ⅳ3)均未发现该位点突变。结论结合临床资料和生物信息学预测,推测CACNA1S、SCN4A、KCNE3基因突变均非该家系致病性突变基因。但该家系资料丰富了我国原发性低钾型周期性麻痹家系的临床和基因数据库。除KCNE3、CACNA1S和SCN4A基因外,中国低钾型周期性麻痹家系可能存在新的致病基因突变,尚待进一步研究。     

遗传性痉挛性截瘫一家系的临床特点与遗传学分析

目的 探讨遗传性痉挛性截瘫(HSP)一家系的基因型和临床特点.方法 抽取1个HSP家系15名成员外周血,选择与已知HSP致病基因位点在物理距离上紧密连锁的微卫星分子进行标记[短串联重复序列(STR)],连锁分析并构建单体型.对患者进行观察,行心肌酶学、肌电图以及头颅、颈髓、胸髓MRI检查,总结其临床特点.结果 家系成员SIR的扩增产物进行基因分型,连锁分析发现与HSP 31型(SPG31)位点连锁,2个SIR(D2S2951、D2S2333)最大LOD值为1.8,表明连锁.经过连锁分析后得到的对应致病基因为REEP1基因,经过突变筛查发现了1个REEP1 c417+1G＞A杂合突变.SPG31临床特点以痉挛步态、下肢肌张力增高为主要表现,MRI显示胸髓萎缩.结论 SPG31患者临床特征表现为典型的HSP特征,致病基因为REEP1基因,存在REEP1 c417+1G＞A杂合突变.     

Mutation analysis of SPG4 and SPG3A genes and its implication in molecular diagnosis of Korean patients with hereditary spastic paraplegia

BACKGROUND: Hereditary spastic paraplegia (HSP), a genetically and clinically heterogeneous group of neurodegenerative disorders, is characterized by progressive lower limb weakness and spasticity. Among the 8 loci associated with the autosomal dominant uncomplicated HSP (AD-HSP), the spastin (SPG4) and atlastin (SPG3A) genes have been known to account for approximately 40% and 10% of all cases, respectively. OBJECTIVE: To investigate the contribution of these 2 genes in the occurrence of HSP in Korean patients. DESIGN: Clinical and genetic study. SETTING: Tertiary care center. PATIENTS: Eighteen patients with uncomplicated HSP (11 AD and 7 sporadic) underwent screening for gene mutation. MAIN OUTCOME MEASURES: Mutations in the SPG4 and SPG3A genes as detected by direct sequencing of all coding exons and flanking intronic sequences. RESULTS: We identified 8 different SPG4 mutations, 7 of which have not been reported elsewhere. Among the detected mutations were 3 missense mutations, 2 in-frame deletions, 2 frameshift mutations, and 1 splice-site mutation. No mutation was found in the SPG3A gene. CONCLUSION: Compared with previous studies, a higher frequency of SPG4 gene mutations in AD-HSP (7/11; 64%) was observed, suggesting that a mutation analysis for the SPG4 gene might be helpful for molecular diagnosis of AD-HSP in Korean patients.     

Pure adult-onset Spastic Paraplegia caused by a novel mutation in the KIAA0196 (SPG8) gene

SPG8 is a rare autosomal dominant hereditary spastic paraplegia (AD-HSP), with only six SPG8 families described so far. Our purpose was to screen for KIAA0196 (SPG8) mutations in AD-HSP patients and to investigate their phenotype. Extensive family investigation was performed after positive KIAA0196 mutation analysis, which was part of an on-going mutation screening effort in AD-HSP patients. A novel pathogenic KIAA0196 mutation p.(Gly696Ala) was identified in two AD-HSP patients, who subsequently were shown to belong to a single large Dutch pedigree with more than 10 affected family members. The phenotype consisted of a pure HSP with ages at onset between 20 and 60 years, distally reduced vibration sense in the legs in all, and urinary urgency in seven out of 10 patients. Frequent features were exercise- or emotion-induced increase of spasticity and gait problems and chronic nonspecific lower back and joint pains. We have identified a fourth pathogenic KIAA0196 mutation in a Dutch HSP-family, the seventh family worldwide, with a less severe clinical course than described before.     

Chinese patients with Machado-Joseph disease presenting with complicated hereditary spastic paraplegia

Background and purpose:  The clinical overlap between Machado-Joseph disease (MJD) and autosomal dominant complicated hereditary spastic paraplegia (AD-HSP) is extensive and the differentiation between them can be difficult on clinical ground. However, patients are seeking the right diagnosis and it is important for neurologists to distinguish them in the early stage.
Methods:  In recent 10 years, we have recruited and followed-up three families which were initially diagnosed as complicated AD-HSP based on the clinical criteria. Mutation analyses of SPG4 , SPG3A and ATXN3 were performed in the index cases.
Results:  No mutations on SPG4 and SPG3A were found. Mutation analysis of ATXN3 showed that these cases have one expanded allele and one normal allele. The copy numbers of CAG repeats were 80/28, 86/28 and 83/33, respectively.
Conclusions:  The molecular diagnosis confirmed that they were MJD patients though they had been misdiagnosed as complicated AD-HSP for many years. The copy numbers of expanded allele were more than 80 and the copy numbers of normal allele were more than 27, which could somewhat explain the earlier onset age of these cases and the anticipation of the pedigrees. Our data emphasize the necessity to perform the mutation analysis of ATXN3 in clinically diagnosed complicated AD-HSP patients.     

De novo occurrence of novel SPG3A/atlastin mutation presenting as cerebral palsy

BACKGROUND: Mutations in the SPG3A gene (atlastin protein) cause approximately 10% of autosomal-dominant hereditary spastic paraplegia. For many subjects with an SPG3A mutation, spastic gait begins in early childhood and does not significantly worsen even over many years. Such subjects resemble those with spastic diplegic cerebral palsy. To date, only 9 SPG3A mutations have been reported. OBJECTIVE: To analyze the SPG3A coding sequence in an individual with childhood-onset spastic gait, who, prior to the birth of her similarly affected child, had no previous family history of hereditary spastic paraplegia. METHODS: The SPG3A coding sequence was analyzed in DNA samples from the proband, her affected child, her unaffected parents, and control subjects by polymerase-chain-reaction amplification of each exon followed by direct DNA sequencing. Seventeen microsatellite polymorphisms were amplified and analyzed to confirm reported paternity. RESULTS: We identified a novel SPG3A mutation (L157W) in the proband and her affected child. This mutation was absent in the proband's unaffected parents. Results of microsatellite polymorphism analysis were consistent with paternity as reported. These results indicate that this novel SPG3A mutation arose de novo in the proband. CONCLUSIONS: We report the de novo occurrence of a novel SPG3A mutation in a subject with childhood-onset, nonprogressive, spastic diplegia who had no previous family history of hereditary spastic paraplegia until the birth of her similarly affected son. Although rare, the occurrence of a de novo hereditary spastic paraplegia gene mutation must be considered in subjects with spastic diplegic cerebral palsy for whom no other cause is identified. This is extremely important for correct genetic counseling because recurrence risk may be as high as 50% when a mutation is detected.     

Hereditary spastic paraplegia with cerebellar ataxia: a complex phenotype associated with a new SPG4 gene mutation

Complex forms of hereditary spastic paraplegia (HSP) are rare and usually transmitted in an autosomal recessive pattern. A family of four generations with autosomal dominant hereditary spastic paraplegia (AD-HSP) and a complex phenotype with variably expressed co-existing ataxia, dysarthria, unipolar depression, epilepsy, migraine, and cognitive impairment was investigated. Genetic linkage analysis and sequencing of the SPG4 gene was performed and electrophysiologic investigations were carried out in six individuals and positron emission tomography (PET) in one patient. The disease was linked to the SPG4 locus on chromosome 2p as previously reported for pure HSP. Sequence analysis of the SPG4 (spastin) gene identified a novel 1593 C > T (GLN490Stop) mutation leading to premature termination of exon 12 with ensuing truncation of the encoded protein. However, the mutation was only identified in those individuals who were clinically affected by a complex phenotype consisting of HSP and cerebellar ataxia. Other features noted in this kindred including epilepsy, cognitive impairment, depression, and migraine did not segregate with the HSP phenotype or mutation, and therefore the significance of these features to SPG4 is unclear. Electrophysiologic investigation showed increased central conduction time at somatosensory evoked potentials measured from the lower limbs as the only abnormal finding in two affected individuals with the SPG4 mutation. Moreover, PET of one patient showed significantly relatively decreased regional cerebral blood flow in most of the cerebellum. We conclude that this kindred demonstrates a considerable overlap between cerebellar ataxia and spastic paraplegia, emphasizing the marked clinical heterogeneity of HSP associated with spastin mutations.     

Early onset autosomal dominant spastic paraplegia caused by novel mutations in SPG3A

Hereditary spastic paraplegia (HSP) is a group of neurodegenerative disorders mainly characterized by progressive spasticity of the lower limbs. The major features of HSP are a marked phenotypic variability both among and within families and an extended genetic heterogeneity. More than 20 HSP loci and 10 spastic paraplegia genes ( SPG) have been identified to date, including the genes responsible for the two most frequent forms of autosomal dominant spastic paraplegia (AD-HSP), encoding spastin ( SPG4) and atlastin ( SPG3A), respectively. To date, only eight mutations have been described in the atlastin gene, which was reported to account for about 10% of all AD-HSP families. We investigated 15 German and French AD-HSP families, including the 3 large pedigrees that allowed the mapping and subsequent refinement of the SPG3A locus. Three novel mutations were found in exons 4, 9, and 12 of the atlastin gene and the common R239C mutation located in exon 7 was confirmed in a 7th family of European origin. Overall, the comparison of the clinical data for all SPG3A-HSP families reported to date failed to reveal any genotype/phenotype correlation as demonstrated for other forms of AD-HSP. However, it confirmed the early onset of this form of HSP, which was observed in almost all affected individuals with a mutation in the atlastin gene.     

Novel mutation in the SPG3A gene in an African American family with an early onset of hereditary spastic paraplegia

BACKGROUND: Mutations in a novel GTPase gene SPG3A cause an autosomal dominant hereditary spastic paraplegia linked to chromosome 14q (SPG3), which accounts for approximately 10% to 15% of all autosomal dominant hereditary spastic paraplegia cases. The mutational spectrum of the SPG3A gene and the phenotype/genotype correlations have not yet been established. OBJECTIVE: To describe a kindred with an infantile onset of hereditary spastic paraplegia caused by a novel mutation in the SPG3A gene. PATIENTS: Complete neurological examination and genetic analysis were performed on 6 affected members of a small African American kindred. Linkage analysis to genetic markers near autosomal dominant hereditary spastic paraplegia loci on chromosomes 2p and 14q was performed. The coding sequence of the SPG3A gene was analyzed, and the identified change in the sequence was tested for being a benign polymorphism by sequencing 200 chromosomes from normal controls. RESULTS: Every affected individual had signs of uncomplicated spastic paraparesis without additional neurological abnormalities. None of the affected family members had ever walked normally. The history was consistent with an infantile onset, despite the normal acquisition of motor milestones. Genetic analysis suggested linkage to the SPG3A locus on chromosome 14q. Analysis of the SPG3A gene revealed a missense mutation C635T, predicted to result in a threonine to isoleucine substitution at codon 156. Analysis of 200 normal chromosomes did not identify the same change in healthy subjects. CONCLUSION: We report a novel mutation in the SPG3A gene in an African American family with an infantile onset of autosomal dominant hereditary spastic paraplegia.     

Spectrum of SPG4 mutations in a large collection of North American families with hereditary spastic paraplegia

BACKGROUND: Hereditary spastic paraplegia (HSP) is a neurodegenerative disease characterized by progressive spasticity and weakness of the lower limbs. The most common form of HSP is caused by mutations in the SPG4 gene, which codes for spastin, an adenosine triphosphatase with various cellular activities (AAA) protein family member. OBJECTIVE: To investigate a large collection of predominantly North American patients with HSP for mutations in the spastin encoding gene, SPG4. METHODS: DNA from 76 unrelated affected individuals was studied for mutations by single-stranded conformational polymorphism analysis and direct sequencing. Each new variant identified was then analyzed in 80 control subjects to determine whether the variant is a common polymorphism or a rare mutation. All DNA samples were amplified by polymerase chain reaction, followed by electrophoresis and autoradiography. RESULTS: We identified 8 novel mutations and 5 previously reported mutations in 15 affected individuals. The novel mutations are 4 missense, 1 nonsense, 1 frameshift, and 2 splice mutations. Two polymorphisms (one in an affected individual) were also identified. CONCLUSIONS: Our collection of families with HSP is different on a genetic level from those previously described. The percentage of our families with a SPG4 mutation is 10% lower than the 40% estimate of families with autosomal dominant HSP noted to be linked to this locus, and splice mutations are not predominant in our collection. Interestingly, we also identified 2 recurring mutations in specific populations (R562Q and G559D), which may facilitate the development of future spastin diagnostic testing in these populations.     

Eight novel mutations in SPG4 in a large sample of patients with hereditary spastic paraplegia

BACKGROUND: Hereditary spastic paraplegia (HSP) is a group of genetically heterogeneous disorders characterized by progressive spasticity of the lower limbs. Mutations in the SPG4 gene, which encodes spastin protein, are responsible for up to 45% of autosomal dominant cases. OBJECTIVE: To search for disease-causing mutations in a large series of Italian patients with HSP. DESIGN: Samples of DNA were analyzed by direct sequencing of all exons in SPG4. Samples from a subset of patients were also analyzed by direct sequencing of all exons in SPG3A, SPG6, SPG10, and SPG13. SETTING: Molecular testing facility in Italy. PATIENTS: Sixty unrelated Italian patients with pure (n = 50) and complicated (n = 10) HSP. MAIN OUTCOME MEASURES: Mutations in SPG4, SPG3A, SPG6, SPG10, and SPG13. RESULTS: We identified 12 different mutations, 8 of which were novel, in 13 patients. No mutations of any of the other HSP genes tested were found in 15 patients with sporadic pure HSP who did not have mutations in the SPG4 gene. CONCLUSIONS: The overall rate of mutation in the SPG4 gene within our sample was 22%, rising to 26% when only patients with pure HSP were considered. The negative result obtained in 15 patients without mutations in SPG4 in whom 4 other genes were analyzed (SPG3A, SPG6, SPG10, and SPG13) indicate that these genes are not frequently mutated in sporadic pure HSP.     

SPG3A mutation screening in English families with early onset autosomal dominant hereditary spastic paraplegia

Mutations in the SPG3A gene encoding the novel GTPase atlastin have recently been implicated in causing autosomal dominant hereditary spastic paraplegia (ADHSP) in six unrelated families. The phenotype of affected individuals in all cases has been of an early onset uncomplicated form of the disease. One particular missense mutation, R239C, in exon 7 of SPG3A has been identified in three of these families. We performed mutation screening by direct sequencing of all 14 exons and flanking sequences of the SPG3A gene in affected individuals from 12 unrelated English families, all with an early onset uncomplicated ADHSP in whom spastin mutations had previously been excluded. The R239C mutation was found to co-segregate with the disease in one English ADHSP family confirming a widespread prevalence for this commonly occurring mutation. No additional SPG3A mutations were identified in the remaining 11 families suggesting that even within this specific sub-set of early onset uncomplicated ADHSP patients atlastin mutations are relatively rare.